文献速递膀胱癌与上尿路尿路上皮癌

膀胱癌诊疗对联邦医疗保险(Medicare)的费用影响

The Cost to Medicare of Bladder Cancer Care.
PubMed 文献 · Eur Urol Oncol · 2019-02-08

本研究利用1998-2013年SEER-Medicare数据开展病例对照研究,按诊断年份、年龄、性别、种族及31项Elixhauser合并症指数进行倾向评分匹配,比较1998、2003、2008三个 incident 队列的膀胱癌患者与对照者的Medicare支付。结果显示诊断后第1年增量费用最高,远处癌高于区域癌和局部癌;长期生存者16年累计费用较对照高46%。

要点

  • 诊断后第1年增量费用最高,远处癌47533美元、区域癌42403美元、局部癌14304美元。
  • 1998至2008年膀胱癌患者诊断时年龄更大、合并症更多,但无分期迁移或生存变化。
  • 长期生存者16年累计Medicare费用172426美元,较对照高46%。

核心结论

  • 膀胱癌诊断初期产生高额Medicare费用,尤其晚期患者,但长期生存者的累计费用更高。
  • 膀胱癌预防可节省Medicare费用;早期检测、更好治疗和延长生命是值得的目标,但会增加Medicare支出。

研究设计与样本

  • 病例对照研究,使用1998-2013年监测、流行病学和最终结果(SEER)-Medicare数据。
  • 对照按诊断年份、年龄、性别、种族和31项Elixhauser合并症指数值进行倾向评分匹配。
  • 比较1998年(n=3136)、2003年(n=7000)和2008年(n=7002)三个 incident 队列。

主要发现

  • 1998年至2008年,膀胱癌患者诊断时更年老且合并症更多,但未发生分期迁移或生存变化。
  • 增量费用在诊断后第1年最高,远处癌为47533美元,高于区域癌的42403美元和局部癌的14304美元。
  • 膀胱癌生存高度依赖分期;费用初始峰值持续1-2年后,生存者月度费用下降但仍高于对照。
  • 全样本中长期生存者16年累计Medicare费用为172426美元,较对照高46%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 局限性包括未纳入间接费用和依赖传统Medicare。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bladder cancer care is costly, including cost to Medicare, but the medical cost associated with bladder cancer patients relative to identical persons without bladder cancer is unknown. OBJECTIVE: To determine incremental bladder cancer cost to Medicare and the impact of diagnosis stage and bladder cancer survival on cost. DESIGN, SETTING, AND PARTICIPANTS: A case-control study was conducted using 1998-2013 Surveillance, Epidemiology and End Results-Medicare data. Controls were propensity score matched for diagnosis year, age, gender, race, and 31 Elixhauser Comorbidity Index values. Three incident cohorts, 1998 (n=3136), 2003 (n=7000), and 2008 (n=7002), were compared. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Survival following diagnosis and Medicare payments (in 2018 dollars) were tabulated, and compared between cases and controls. RESULTS AND LIMITATIONS: From 1998 to 2008, bladder cancer patients became older and had more comorbidities at diagnosis, although no stage migration or change in survival occurred. Incremental costs (above those associated with controls) were highest during the 1st year after diagnosis and were higher for distant ($47533) than for regional ($42403) or localized ($14304) cancer. Bladder cancer survival was highly stage dependent. After an initial spike in costs lasting 1-2yrs, monthly costs dropped in survivors but remained higher than for controls. Long-term survivors in the full sample accrued cumulative Medicare costs of $172426 over 16yrs-46% higher than for controls. Limitations include omission of indirect costs and reliance on traditional Medicare. CONCLUSIONS: While a bladder cancer diagnosis incurs initial high Medicare cost, particularly in patients with advanced cancers, the cumulative costs of bladder cancer in long-term survivors are higher still. Bladder cancer prevention saves Medicare money. However, while early detection, better therapies, and life extension of bladder cancer patients are worthwhile goals, they come at the cost of higher Medicare outlays. PATIENT SUMMARY: The lifetime cost of bladder cancer, reflecting surveillance, treatment, and management of complications, is substantial. Since care is ongoing, cost increases with the length of life after diagnosis as well as the severity of initial diagnosis.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Sloan FA, Yashkin AP, Akushevich I, et al. The Cost to Medicare of Bladder Cancer Care. Eur Urol Oncol. 2019. PMID: 31412015. doi:10.1016/j.euo.2019.01.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。